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The World Health Organization (WHO) deﬁnes osteopenia as a bone density between 1 and 2.5 standard deviation (SD) below
the bone density of a normal young adult Iqbal 2000. Osteoporosis is deﬁned as 2.5SD or more below that reference point Iqbal
2000. Bisphosphonates are a group of medications used to treat osteoporosis, Padget’s disease of bone, and osteopenia. We report
a woman who developed profound muscle weakness and pain after one dose of Risedronate (Actonel).
Copyright © 2009 I. Badayan and M. E. Cudkowicz. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1.Introduction
Risedronate (Actonel) is a bisphosphonate used for the
treatment of osteopenia that inhibits bone resorption via
actions on osteoclasts or osteoclast precursors, leading to an
increase in bone mineral density. Pharmacologic therapy for
osteopeniaisrecommendedasearlyaspossibletopreventthe
g r e a t e rb o n el o s s[ 1]. The most common side eﬀects of Rise-
dronate include fever and ﬂu-like symptoms, hypocalcemia,
bone and joint pain, peripheral edema, fatigue, change
in bowel movements, osteonecrosis of the jaw, and atrial
ﬁbrillation [2] .W ed e s c r i b eac a s er e p o r to fs e v e r ew e a k n e s s
as a potential new side eﬀect of Risedronate in a woman with
osteopenia.
2.CaseReport
A 53-year-old Caucasian woman presented with diﬀuse
muscle weakness and pain. Past medical history was notable
for gastroesophageal reﬂux disease, diverticulitis, intermit-
tent lower back pain, and osteopenia. She took one dose
of Risedronate, 35mg for osteopenia. Within 15 hours,
she developed severe aching muscle pain (10/10 on Visual
Analog Scale) throughout the body with fevers, sweats,
chills, tingling throughout the body, and loss of bladder
control. In the Emergency Room, she was told she had a
drug reaction from Risedronate and prescribed oxycontin
for pain management. Evaluation included normal complete
blood counts and electrolytes. Potassium and creatinine
were mildly low at 3.4mEq/L, and 0.5mg/dL, respectively.
The CO2 was elevated at 31.4mEq/L (normal range 22.0–
29.0mEq/L), Calcium, creatine phosphokinase (CPK) and
ESR were normal. Neurological examination in the emer-
gency room was notable for decreased strength in proximal
lower extremities graded at 4−/5 using the Medical Research
Council(MRC)scale.Deeptendonreﬂexeswerenormal.The
only medications patient was taking at the time of the event
were Nexium 40mg per day and Posture D vitamins.
Over the next three weeks, she developed severe muscle
cramps, bilateral lower extremity edema, and progressive
muscle weakness and could not raise her arms above her
head. She had several falls and became wheelchair bound.
Diﬀuse pain (8/10 on VAS) in the bones and muscles of her
limbs and back was present.
She underwent electromyography (EMG) testing which
demonstrated mild bilateral median neuropathies bilaterally
and active denervation (ﬁbrillations and positive sharp
waves)onlyintherightdeltoidmuscle.MRIofcervicalspine
was normal. Methylpresnisolone, 24mg with a six day taper
was prescribed without clinical beneﬁt.
One month post dose, she had proximal weakness
in the upper and lower extremities with bilateral deltoid
graded at MRC 3−/5, hip ﬂexors at 3−/5, and hamstrings
at 4/5. Proximal muscle weakness was evident on gait
testing. She was admitted to an outside hospital. During
her stay, the work up for following diﬀerential diagnosis2 Case Reports in Medicine
was done: multiple myeloma, Gullian-Barr´ e syndrome,
chronic inﬂammatory demyelinating polyneuropathy. Sys-
temic Lupus Erythematosus, Waldestrom’s macroglobuline-
mia, Cushing disease, myasthenia gravis, hyperparathy-
roidism, and polymyalgia rheumatica. Work up included
an MRI of brain with and without gadolinium, a lumbar
puncture for cerebrospinal ﬂuid analysis, and a whole
body positron emission tomography scan, all which were
normal. MRI of the muscle was not performed. Results
of a second EMG study were similar to the previous test
with the exception that the active denervation changes in
right deltoid were absent. A muscle biopsy was considered
at the beginning of the hospitalization, but was deferred
because her aldolase and repeat CPK tests were normal. She
started a program of physical and occupational therapy, and
acupuncture.
The pain and weakness began to slowly subside approx-
imately four months after the dose. By six months postdose,
she improved to the point that she no longer needed a cane
to ambulate. One year postdose, she reports easy fatigability,
severe pain (7/10 on VAS) in the left biceps and back,
and mild weakness in her legs. She has diﬃculty going up
the stairs and standing from a lying position. Neurological
examination was notable for mild proximal lower extremity
a n dh a n dw e a k n e s sw i t hM R Cg r a d e so f4 +i l i o p s o a s ,5 −
abductor pollicis brevis, 4+ abductor digiti minimi, and
4+ ﬁrst dorsal interosseous bilaterally with some weakness
on the ﬁnger extensions. No atrophy or fasciculations
were seen.
Two and a half years after taking one pill of Risedronate,
the patient continues to improve. She reports some weakness
of her shoulders, diﬃculty carrying heavy things, and some
shortness of breath with exertion. Recently, she underwent
quantitative muscle testing (QMT) to asses her muscle
weakness [3]. Isometric strength of ten muscle groups
was measured bilaterally. Her percent of predicted strength
valuesindicatedextensiveweaknessthroughout,withmuscle
strength of diﬀerent muscle groups ranging from 31.5% to
76.4%, with the mean strength 50.5%.
A MedWatch form was ﬁled with the FDA.
3. Discussion
We describe a 53-year-old woman who developed a severe
pain and weakness after taking one pill of Risedronate for
treatment of osteopenia. The side eﬀect of medication was so
profound that patient lost ability to ambulate and two and a
half years later is still not completely recovered.
According to 2004 Surgeon General report on bone
health and osteoporosis, 33.6 million individuals over age 50
havelowbonemassorosteopeniaofthehipandareatriskof
osteoporosis and its potential complications. The prevalence
of osteoporosis and low bone mass is expected to increase to
12 million cases of osteoporosis and 40 million cases of low
bone mass among individuals over the age of 50 by 2010, and
to nearly 14 million cases of osteoporosis and over 47 million
cases of low bone mass in individuals over that age by 2020
[4]. Bisphosphonates are approved for treatment of Paget’s
disease of bone, osteoporosis, and osteopenia.
Absorption of Risedronate after the oral dose is relatively
rapid (Tmax 1 hour). There is no evidence of systemic
metabolism of Risedronate with 80% of the drug excreted
with urine and 20% absorbed by bone. Bioavailability of
Risedronate sodium is poor (0.54%–0.75%) and half-life
is 480 hours. Approximately half of the absorbed dose is
excreted in urine within 24 hours [2].
Risedronate was used in the treatment of the patient pre-
sented in this case report. The FDA has received six serious
adverse event reports of severe bone, joint, or muscle pain
for this medication [5]. Pain (described as “incapacitating,”
“disabling”) and loss of ability to climb stairs, ambulate, and
perform the usual activities were reported as side eﬀects of
ad i ﬀerent bisphosphonate, Alendronate (Fosamax), which
may suggest a possible class eﬀect [5]. According to the
FDA article published in 2006, many patients underwent
numerous diagnostic tests with mostly normal ﬁndings [5,
6]. Details on the exact number of patients and the names
of diagnostic tests patients performed are not provided.
There have not been other reported cases of proximal muscle
weakness after Risedronate use.
Symptoms experienced by the patient described in this
case report (rise in temperature and accompanying ﬂu-
like symptoms) resemble an acute phase response. The
mechanism for this response in general appears to be
associated with the release of tumor necrosis factor (TNF)α,
interferon γ (INF-γ), interleukin 1 (IL1), and interleukin 6
(IL-6) although the eﬀector cells that release these cytokines
and the mechanism of action remains not completely under-
stood [7]. Aminobisphosphonates (including Risedronate)
increase serum levels of proinﬂammatory cytokines [8].
Therefore, it is possible that patient’s muscle weakness
might be an inﬂammatory response to the drug toxicity.
Such hypothesis cannot be supported by patient’s levels of
proinﬂammatory cytokines because they were not measured
during the course of the disease. Muscle biopsy was not
performed in this case, however will be an essential test
to perform in similar cases to better assess etiology of
symptoms. Pain and muscle weakness as adverse events of
Risedronate may be underreported and not taken into con-
siderationbecauseofthesubjectivenatureofpain,confusion
with the pain from osteoporosis, and attribution of the loss
of ambulation to pain. Combined with normal diagnostic
tests, it may result in failure to recognize this potential side
eﬀect and a delay in stopping the bisphosphonate. Four
of the bisphospohonates are listed in the Top 200 Brand
Drugs By Units in 2007 accounting for almost 31 million
prescriptions [9]. Given the number of patients receiving
bisphosphonate therapy and the paucity of reports, the
incidence of the complex of symptoms is assumed to be
relatively low. However, the formal reporting of adverse drug
events is known to understate their true incidence [10, 11].
For each patient, decisions regarding the therapy must
also take into consideration the long period of treatment,
substantial costs, and potential side eﬀects. At this point, the
risk factors and incidence of the incapacitating muscle pain
and profound muscle weakness are unknown. Additional
studies are needed to investigate the possible mechanism of
pain,muscleweakness,andedemafollowingbisphosphonateCase Reports in Medicine 3
treatment. Even if low, the awareness of these side eﬀects is
veryimportantbecauseoftheseriousnatureoftheproblem.
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